homeWelcome, sign in or click here to subscribe.login
     


 

 

Business


print  email to a friend  reprints add to mydjc  

August 13, 2020

Omeros

Seattle-based biopharmaceutical company Omeros priced an offering of 6.9 million shares of common stock at $14.50 per share and a separate offering of $210 million in 5.25% convertible senior notes due in 2026. The offerings are expected to close on Friday and include options to purchase up to 1.04 million additional shares and $31.5 million in notes. Omeros will use $297.4 million in net proceeds for general corporate purposes and to repurchase about $115 million of existing 6.25% convertible senior notes due in 2023.




Email or user name:
Password:
 
Forgot password? Click here.